ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016

– Preclinical data relevant for multiple sclerosis and other neurodegenerative diseases – NEW YORK, NY – February 17, 2016 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…